Another explanation for urinary tract problems in schizophrenic patients.
D000978:Antiparkinson Agents / Q000009:adverse effects; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000627:therapeutic use; D004327:Drinking Behavior / Q000187:drug effects; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology* / Q000517:prevention & control; D006984:Hypertrophy; D011619:Psychotropic Drugs / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D001745:Urinary Bladder Diseases / Q000209:etiology* / Q000517:prevention & control; D014987:Xerostomia / Q000139:chemically induced
D000978:Antiparkinson Agents; D001626:Bethanechol Compounds; D011619:Psychotropic Drugs; D018723:Bethanechol